{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:10:22Z","timestamp":1792444222848,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40261-026-01535-1","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:00:24Z","timestamp":1772096424000},"page":"541-549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost Effectiveness of Osimertinib with Chemotherapy Compared to Osimertinib Monotherapy and First-Generation EGFR-TKIs in Advanced NSCLC in the USA"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9329-1101","authenticated-orcid":false,"given":"Mohammad","family":"Alnuman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-9398","authenticated-orcid":false,"given":"Kangho","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"8","key":"1535_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.35128","volume":"130","author":"TB Kratzer","year":"2024","unstructured":"Kratzer TB, Bandi P, Freedman ND, Smith RA, Travis WD, Jemal A, et al. Lung cancer statistics, 2023. Cancer. 2024;130(8):1330\u201348.","journal-title":"Cancer"},{"issue":"1","key":"1535_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1535_CR3","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s12325-024-02799-9","volume":"41","author":"M Khasraw","year":"2024","unstructured":"Khasraw M, Yalamanchili P, Santhanagopal A, Wu C, Salas M, Meng J, et al. Clinical management of patients with non-small cell lung cancer, brain metastases, and actionable genomic alterations: a systematic literature review. Adv Ther. 2024;41(5):1815\u201342.","journal-title":"Adv Ther"},{"issue":"8","key":"1535_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623\u201340.","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"1535_CR5","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","volume":"24","author":"S Dearden","year":"2013","unstructured":"Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24(9):2371\u20136.","journal-title":"Ann Oncol"},{"key":"1535_CR6","unstructured":"National Cancer Institute; Surveillance, Epidemiology, and End Results Program. SEER cancer stat facts: lung and bronchus cancer. 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html. Accessed 23 Feb 2026."},{"issue":"17","key":"1535_CR7","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1200\/JCO.2014.58.1736","volume":"33","author":"CK Lee","year":"2015","unstructured":"Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J Clin Oncol. 2015;33(17):1958\u201365.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1535_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35961-y","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023;14(1):1070.","journal-title":"Nat Commun"},{"issue":"2","key":"1535_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"21","key":"1535_CR10","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935\u201348.","journal-title":"N Engl J Med"},{"key":"1535_CR11","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer (Version 10.2024). https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450. Accessed 1 Dec 2024."},{"issue":"7","key":"1535_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629\u201340.","journal-title":"N Engl J Med"},{"issue":"10","key":"1535_CR13","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","volume":"29","author":"BC Cho","year":"2023","unstructured":"Cho BC, Kim DW, Spira AI, Gomez JE, Haura EB, Kim SW, et al. Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Nat Med. 2023;29(10):2577\u201385.","journal-title":"Nat Med"},{"issue":"1","key":"1535_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","volume":"38","author":"C Smare","year":"2020","unstructured":"Smare C, Lakhdari K, Doan J, Posnett J, Johal S. Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. Pharmacoeconomics. 2020;38(1):97\u2013108.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1535_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials: extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743\u201354.","journal-title":"Med Decis Making"},{"issue":"1","key":"1535_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350.","journal-title":"N Engl J Med"},{"issue":"8","key":"1535_CR17","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","volume":"8","author":"C Chouaid","year":"2013","unstructured":"Chouaid C, Agulnik J, Goker E, Herder GJ, Lester JF, Vansteenkiste J, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8(8):997\u20131003.","journal-title":"J Thorac Oncol"},{"key":"1535_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6:84.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"1535_CR19","first-page":"544","volume":"24","author":"J Graham","year":"2018","unstructured":"Graham J, Earnshaw S, Burslem K, Lim J. Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. health plan. J Manag Care Spec Pharm. 2018;24(6):544\u201353.","journal-title":"J Manag Care Spec Pharm"},{"key":"1535_CR20","unstructured":"U.S. Department of Health and Human Services. Medicare Part B drug average sales price. Baltimore: U.S. Department of Health and Human Services; 2024. Contract No.: 12\/2024."},{"key":"1535_CR21","unstructured":"U.S. Department of Veterans Affairs. Federal Supply Schedule (FSS) pharmaceutical pricing. Washington, DC: U.S. Department of Veterans Affairs; 2024."},{"key":"1535_CR22","doi-asserted-by":"crossref","unstructured":"Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, eds. Cost-effectiveness in Health and Medicine, 2nd ed. Oxford University Press; 2017. New York, NY.","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001"},{"issue":"8","key":"1535_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.2530","volume":"5","author":"M Serra-Burriel","year":"2024","unstructured":"Serra-Burriel M, Martin-Bassols N, Per\u00e9nyi G, Vokinger KN. Drug prices after patent expirations in high-income countries and implications for cost-effectiveness analyses. JAMA Health Forum. 2024;5(8):e242530.","journal-title":"JAMA Health Forum"},{"issue":"3","key":"1535_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40273-022-01230-x","volume":"41","author":"RB McQueen","year":"2023","unstructured":"McQueen RB, Anderson KE, Levy JF, Carlson JJ. Incorporating dynamic pricing in cost-effectiveness analysis: are known unknowns valuable? Pharmacoeconomics. 2023;41(3):321\u20137.","journal-title":"Pharmacoeconomics"},{"key":"1535_CR25","unstructured":"Centers for Medicare & Medicaid Services. Medicare physician fee schedule 2024. Baltimore: Centers for Medicare and Medicaid Services; 2024. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search. Accessed 1 Dec 2024."},{"key":"1535_CR26","unstructured":"Services CfMM. Clinical laboratory fee schedule. Baltimore: Centers for Medicare and Medicaid Services; 2024. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs. Accessed 23 Feb 2025."},{"issue":"9","key":"1535_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2026","volume":"7","author":"KN Vokinger","year":"2021","unstructured":"Vokinger KN, Hwang TJ, Daniore P, Lee CC, Tibau A, Grischott T, et al. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. JAMA Oncol. 2021;7(9):e212026.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1535_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/cpt.1983","volume":"109","author":"BN Rome","year":"2021","unstructured":"Rome BN, Lee CC, Kesselheim AS. Market exclusivity length for drugs with new generic or biosimilar competition, 2012\u20132018. Clin Pharmacol Ther. 2021;109(2):367\u201371.","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"1535_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70083","volume":"13","author":"W Tian","year":"2024","unstructured":"Tian W, Niu L, Zhou R, Wang Z, Ning J, Lu R, et al. Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Med. 2024;13(16):e70083.","journal-title":"Cancer Med"},{"issue":"3","key":"1535_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1634\/theoncologist.2018-0150","volume":"24","author":"B Wu","year":"2019","unstructured":"Wu B, Gu X, Zhang Q, Xie F. Cost-effectiveness of osimertinib in treating newly diagnosed, advanced EGFR-mutation-positive non-small cell lung cancer. Oncologist. 2019;24(3):349\u201357.","journal-title":"Oncologist"},{"issue":"6","key":"1535_CR31","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2217\/fon-2021-0923","volume":"18","author":"BC Cho","year":"2022","unstructured":"Cho BC, Felip E, Hayashi H, Thomas M, Lu S, Besse B, et al. MARIPOSA: phase 3 study of first-line amivantamab\u00a0+\u00a0lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022;18(6):639\u201347.","journal-title":"Future Oncol"},{"key":"1535_CR32","unstructured":"Services CfMM. Medicare severity-Diagnosis Related Group. Baltimore: Centers for Medicare and Medicaid Services; 2024. https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/acute-inpatient-pps\/ms-drg-classifications-and-software. Accessed 23 Feb 2026."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01535-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01535-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01535-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T13:39:49Z","timestamp":1776865189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01535-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1535"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01535-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mohammad Alnuman and Kangho Suh have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study did not require ethical approval as it used only the published literature and publicly available data sources.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data generated or analyzed during this study are included in this published article (and its supplementary information files).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The model is not publicly available. Additional details on the model implementation and analytic approach are available from the authors upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MA: conceptualization; data curation; formal analysis; methodology; validation; writing (original draft preparation); writing (review and editing). KS: methodology; supervision; writing (original draft preparation); writing (review and editing). All authors read and approved the final version and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}